SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellicum Pharmaceuticals, Inc. (BLCM)

NEW YORK, Jan. 31, 2018 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ: BLCM). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/blcm.

The investigation concerns whether Bellicum and certain of its officers and/or directors have violated Federal Securities Laws.

On January 30, 2018, post-market, Bellicum issued a press release announcing “that the Company has received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501”, the Company’s lead product candidate, “have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.” On this news, Bellicum’s share price has fallen sharply during intraday trading on January 31, 2018.

If you are aware of any facts relating to this investigation, or purchased Bellicum shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/blcm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]